By reforming the surface area of PLGA nanoparticles with ligands that target the transferrin receptor or the insulin receptor, researchers have demonstrated enhanced BBB penetration and intracellular delivery of therapeutic agents to dopaminergic neurons in PD experimental models of reducing PD symptomatology [73,74,75]. This evidence concerns the gene TFRC and Parkinson disease.